News >

Novel Agents, Combos Excite in Multiple Myeloma

Angelica Welch
Published: Tuesday, Nov 28, 2017

Dr. Dan T. Vogl
Dan T. Vogl, MD
Researchers are continuing to build on recent success in the field of multiple myeloma, says Dan T. Vogl, MD.

on Hematologic Malignancies, Vogl, director, Abramson Cancer Center Clinical Research Unit, assistant professor of medicine at the Hospital of the University of Pennsylvania, discussed some of these novel agents alone and in combination. He also highlighted the potential with CAR T-cell therapy in the multiple myeloma paradigm.

OncLive: Please provide an overview of your presentation.

Vogl: This is an exciting time to treat patients with multiple myeloma because, in addition to all of the great [therapies] that are already approved for treatment, there are some new options that allow us to keep treating patients for many lines of therapy—and we are getting good responses. One of our newer agents, daratumumab, is being increasingly used in earlier lines of therapy and can now be used in combination with pomalidomide (Pomalyst). I also discussed the upcoming introduction of subcutaneous formulation of daratumumab that will make the infusions a lot shorter for our patients, and make the treatment a lot more convenient. 

Some of the most exciting stuff coming out in myeloma has to do with CAR T-cell therapies. One of the trials that we did at the University of Pennsylvania using a CAR T cell targeted at BCMA had an impressive response rate in early phases and we are continuing to enroll patients. There are additional CAR T-cell studies that are coming up that will be opening soon, and we hope to see good responses there, as well.

Could you expand on nelfinavir and its potential in multiple myeloma?

Nelfinavir is a fascinating story because the trial that showed efficacy was one that was not supported by any drug companies, but supported by academic funds. It was based on the idea that it should make proteasome inhibitor therapy work better. People have been trying to capitalize on the idea that if blocking the proteasome—which is a cellular organelle that degrades proteins—is good for killing myeloma, then we should be able to augment that response by looking at other ways of degrading proteins.


... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x